Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge

The Nasdaq gained 1.05% to 27,477 and reached another record, while the S&P 500 rose 0.66% and the Dow added 0.18%, despite the 10-year Treasury yield rising 0.03% to 5.31%. Risk appetite improved after softer-than-expected jobs data reduced traders’ perceived likelihood of a further Fed rate hike this month; Vaxcyte rose over 30% on positive late-stage vaccine results, Genmab gained nearly 11% on lymphoma drug data, and PTC climbed on reports of a $22.6 billion buyout offer. AI optimism also supported Nvidia, amid speculation its market capitalization could reach $6 trillion, while FactSet data showed nearly 60% of S&P 500 ratings were Buy and a record 72 companies had issued positive Q3 guidance—raising the risk that high expectations could make even earnings beats disappointing.

Analysis

The key tension is between improving risk appetite and a still-high discount rate: if Treasury yields remain elevated, long-duration growth stocks need earnings and cash-flow upgrades—not just a softer near-term Fed path—to sustain multiple expansion. The immediate index advance is therefore vulnerable to a reversal if upcoming results merely meet already-optimistic expectations. Watch earnings revisions and forward guidance breadth, not headline beats alone.

For NVIDIA, continued infrastructure demand supports the thesis, but rising expectations increase the risk that strong results fail to clear the bar; any moderation in hyperscaler capex would matter more than broad AI enthusiasm. The reported Terafab discussions are not evidence of committed orders for Taiwan Semiconductor Manufacturing. If they develop into funded plans, they could reinforce foundry demand but also intensify capacity-allocation and execution questions; absent commitments, they are sentiment, not a revenue catalyst.

The biotech jumps are company-specific readout events, not a read-through to the sector. Without full efficacy, safety, and regulatory details, neither result establishes commercial value or removes further clinical risk. PTC’s reported offer creates deal optionality, but without confirmed terms and a named, committed bidder, the price may embed an unreliable takeover premium. Over the next 1–3 months, earnings and yield direction are broader catalysts; over 6–18 months, realized AI spending and clinical/regulatory progress matter more than today’s risk-on tone.

Key Decisions for Investors

• Avoid chasing broad Nasdaq strength ahead of earnings. For portfolios with concentrated growth exposure, consider a limited QQQ put spread or reduce beta if the 10-year yield holds above roughly 5.3%; reassess if yields retreat and earnings revisions broaden. The hedge thesis is weakened by sustained declines in yields alongside upward estimate revisions.
• Hold existing NVIDIA exposure selectively, but do not add solely on market-cap speculation. Track hyperscaler capex commentary and forward data-center demand; a meaningful capex slowdown or weaker forward guidance would challenge the thesis.
• Treat PTC as a deal-watch, not a merger-arbitrage entry, until a definitive proposal, price, financing, and regulatory path are verified. If no credible offer emerges, reassess against standalone fundamentals rather than anchoring to takeover speculation.
• Do not chase PCVX or GMAB after sharp event-driven moves without reviewing the complete clinical datasets and next regulatory milestones. Missing details to verify include durability, safety, comparator context, and timing; adverse data or a delayed path to approval would falsify the bullish read-through.